Answers are grounded in this paper and cite their sources.
Randomized trial evaluated memory function effects of whole brain radiation therapy with temozolomide, suggesting better outcomes for shorter treatment schedules.
Introduction: Most common intracranial tumor in adults is brain metastasis. Different fractionation schedules used for whole brain radiation therapy are 20gray/5Fr, 30gray/10Fr, and 40gray/20Fr, which in four weeks have shown equivalent response rate, period of improvement, palliative effect, time to disease progression, and survival. However, there is lacking literature on the effect of different fractionation schedules of radiation therapy on memory function. Objectives: Hence, we evaluated memory function in two different fractionation schedules of whole brain radiation therapy (WBRT) inpatients with brain metastases. Methods: Atotal of 50 patients, who were histologically proven primary and recently diagnosed brain metastases, and satisfying eligibility criteria were taken into this study. Patients were randomly assigned to whole brain radiation therapy of 40gray in 20 fractions (group A) and 30gray in 10 fractions (group B) with concurrent Temozolomide. Memory function assessment was done using P.G.I. Memory scale before, during, and after the treatment. Data Analysis And Results: Patients in-group Ashowed improvement in both domains of memory function (Remote and Recent memory) during radiation therapy, compared to group B patients. Discussion & Conclusion: Forty Gray in 20 fractions given over four weeks with concurrent TMZ 75 mg/m2 is a better and preferable treatmentoptionforpatientswithbrainmetastasiswithrespecttomemoryfunction.
No takes yet. Share an insight, caveat, or question.
Sharma et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: